Viatris Inc. reported its financial results for the third quarter of 2024, announcing total revenues of $3.8 billion. The company surpassed Wall Street estimates for both its third-quarter profit and revenue.
On a divestiture-adjusted basis, Viatris achieved approximately 3% operational revenue growth. This performance highlights the underlying strength and resilience of the company's core business operations.
The positive results were partly driven by strong demand for Viatris's new generic asthma and ADHD drugs, among other products. This indicates successful product commercialization and market acceptance within its diversified portfolio.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.